Pay in 4 interest-free payments of $6.37 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Semaglutide placebo participants lost 2.4% body weight
& Karplus, P
The GLP-1 drugs are the latest class to show a benefit in patients, this time with OSA, but like other tools have nontrivial side effects, cost concerns, and patient persistence issues that balance out the headline benefits. The size of the underlying patient populations, which are expected to surpass 1.3 billion globally by 2050, as well as the under penetration of CPAP treatment, which Andrew ballparks at 15% or less in many markets, reinforces the analysts argument
Barry Conrad Melanie, we haven't even thought about this
US$ 25.36
US$ 23.58
US$ 23.73
US$ 22.46
